https://ucla.clinicaltrials.researcherprofiles.org/trial/NCT04094610
UCLA Solid Tumor Trial → Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1,...
This Solid Tumor and Lymphoma study at UCLA is now recruiting people ages up to 25 years.
solid tumorand younguclatrialrepotrectinib
https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-2/the-potential-long-term-comparative-effectiveness-of-larotrectinib-vs-repotrectinib-for-treatment-of-ntrk-gene-fusion-positive-cancers
ISPOR - The Potential Long-Term Comparative Effectiveness of Larotrectinib vs Repotrectinib for...
the potentiallong termcomparative effectivenessisporlarotrectinib
https://www.bmsclinicaltrials.com/at/de/clinical-trials/NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3...
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic...
a studyand youngrepotrectinibpediatricadult